Adaptimmune Therapeutics Manufactures SPEAR T-Cells

Adaptimmune Therapeutics embarks on manufacturing T-cell therapy to treat  cancer entitled SPEAR T-cells for a patient at its Navy Yard facility in Philadelphia. In addition to this Adaptimmune signs an agreement with Cell and Gene Therapy Catapault for producing Vector in the UK ensuring vector supply for its future clinical studies as well as its underway clinical studies.

James Noble, Adaptimmune’s Chief Executive Officer said  “We will continue to work with our cell manufacturing partner PCT, now part of Hitachi, where we have dedicated space and personnel for production of our SPEAR T-cells, as well as our other vector suppliers. Having these dedicated resources both in-house and through external partnerships is essential to ensure our future success as a fully integrated cell therapy company.”

Vector supply has been deferred beyond 2020  for ongoing studies with all three SPEAR T-cell therapies, MAGE-A4, MAGE-A10 and AFP. The agreement, which was executed on January 5, 2018 with Cell and Gene Therapy (CGT) Catapult, will enable Adaptimmune to have its own dedicated vector manufacturing space in the UK.